Back to top
more

Madrigal Pharmaceuticals (MDGL)

(Delayed Data from NSDQ)

$193.33 USD

193.33
453,242

-1.05 (-0.54%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $192.63 -0.70 (-0.36%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth C Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (91 out of 252)

Industry: Medical - Drugs

Better trading starts here.

Brokerage Reports

Research for MDGL

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Madrigal Pharmaceuticals, Inc. [MDGL]

Reports for Purchase

Showing records 1 - 20 ( 184 total )

Company: Madrigal Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 1

03/15/2024

Company Report

Pages: 9

Rezdiffra Achieves Landmark Approval as the First Therapy Indicated for MASH

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Research Provided by a Third Party

Company: Madrigal Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 2

03/12/2024

Company Report

Pages: 9

All Eyes on Resmetirom March 14 PDUFA; EMA Validates MAA; Significant Model Updates; Raise PT to $405

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Research Provided by a Third Party

Company: Madrigal Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 3

01/23/2024

Industry Report

Pages: 6

Enter a New Key Challenger in the MASH Race: Sagimet''s Denifanstat Looks to Enter Phase 3 by YE24

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Research Provided by a Third Party

Company: Madrigal Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 4

11/22/2023

Company Report

Pages: 6

Optimized Entry and Exit Levels for MDGL 112223

Provider: Stock Traders Daily

Analyst: Research Department

Price: 12.50

Research Provided by a Third Party

Company: Madrigal Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 5

11/13/2023

Company Report

Pages: 8

3Q Recap; MAESTRO-NASH Results Prominently Featured in Presentations at AASLD; Increasing PT to $275; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 12.50

Research Provided by a Third Party

Company: Madrigal Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 6

09/14/2023

Daily Note

Pages: 4

Resmetirom''s NDA For NASH Fibrosis Under Priority Review

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 5.00

Research Provided by a Third Party

Company: Madrigal Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 7

09/12/2023

Daily Note

Pages: 3

New CEO Takes the Reins, as the FDA''s Acceptance of the Resmetirom NDA, and Setting the PDUFA Date are Imminent

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 5.00

Research Provided by a Third Party

Company: Madrigal Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 8

12/19/2022

Company Report

Pages: 8

The Whole NASH Field Cheers as MAESTRO-NASH Is a Home Run; Raise PT to $225

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 12.50

Research Provided by a Third Party

Company: Madrigal Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 9

09/01/2022

Daily Note

Pages: 4

MAESTRO-NASH Outcomes NASH Cirrhosis Study Begins; Pivotal MAESTRO-NASH Top-line Results on Target in 4Q22; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 5.00

Research Provided by a Third Party

Company: Madrigal Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 10

08/08/2022

Company Report

Pages: 9

2Q Recap; Top-line Readout of Pivotal Phase 3 MAESTRONASH in 4Q Poised to Be a Watershed Event in NASH; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 12.50

Research Provided by a Third Party

Company: Madrigal Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 11

07/14/2022

Daily Note

Pages: 3

Healthcare Coverage Update - Dropping Coverage

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 5.00

Research Provided by a Third Party

Company: Madrigal Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 12

02/25/2022

Company Report

Pages: 9

4Q Recap: Our Positive Thesis Unfazed by Minor Delay in Pivotal Data Readout to 4Q21

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 12.50

Research Provided by a Third Party

Company: Madrigal Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 13

02/01/2022

Company Report

Pages: 10

Positive Results From MAESTRO-NAFLD-1 Tees Up a Low- Risk Pivotal Biopsy NASH Readout in 3Q22; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 12.50

Research Provided by a Third Party

Company: Madrigal Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 14

12/30/2021

Daily Note

Pages: 3

We See No Negative Read-Through From the Slight Delay of Top-Line Data From MAESTRO-NAFLD-1 to January 2022

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 5.00

Research Provided by a Third Party

Company: Madrigal Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 15

11/19/2021

Daily Note

Pages: 7

Post-AASLD KOL Event Highlights Both Strong Non-Invasive Data and Increasing NIT Correlations to Histology Endpoints

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 12.50

Research Provided by a Third Party

Company: Madrigal Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 16

11/05/2021

Company Report

Pages: 8

3Q21 Recap; Open-Label NAFLD Data Could Provide Early Read-Through By Year-End 2021; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 12.50

Research Provided by a Third Party

Company: Madrigal Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 17

09/28/2021

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for MDGL

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Madrigal Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 18

08/11/2021

Company Report

Pages: 9

2Q Recap: With Pivotal Readout in 3Q22, Resmetirom Poised to Become First-to-Market Therapy in NASH

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Research Provided by a Third Party

Company: Madrigal Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 19

07/01/2021

Daily Note

Pages: 3

MAESTRO-NASH''s Complete Enrollment Sets The Stage For Top-line Data Readout in 3Q22; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 10.00

Research Provided by a Third Party

Company: Madrigal Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 20

05/07/2021

Company Report

Pages: 8

1Q21 Recap; First 52-Week Data With Resmetirom in NAFLD Patients Expected at Major Conference in 2021

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Research Provided by a Third Party